Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2019-11-20 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for NeuroVive Pharmaceutical AB covering the third quarter (Q3) of 2019. It contains detailed financial information, including income statements, earnings per share, and operational updates for the period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q3 2019
2019-11-20 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 1% confidence The document is titled 'NeuroVive Pharmaceutical AB Q3 Interim Report January-September 2019'. It contains comprehensive financial information for the third quarter and the first nine months of 2019, including net revenues, operating income, and loss per share. It also provides detailed business updates, project statuses, and management commentary. As it is a comprehensive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2019
2019-11-20 English
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding, specifically a 'Sell' transaction reason, resulting in the holder's voting rights percentage dropping to 9.99%. It explicitly mentions 'Reason for major shareholding notification Sell' and provides detailed tables showing the 'Before the transaction' and 'After the transaction' holdings, including the number of shares and percentage. This structure is characteristic of a notification regarding a change in significant ownership thresholds. The closest matching category is 'Major Shareholding Notification' (MRQ). The document length is short (3467 chars), but it is the report itself, not an announcement of a report, as it contains the core data. Classification: Major Shareholding Notification (MRQ).
2019-10-04 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for NeuroVive Pharmaceutical AB covering the period January-June 2019. It contains detailed financial information, including income statements, earnings per share, and business performance analysis for the second quarter and the first half of the year. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q2 2019
2019-08-21 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 1% confidence The document is titled 'NeuroVive Pharmaceutical AB Q2 Interim Report January-June 2019'. It contains detailed financial information for the second quarter and the first six months of 2019, including net revenues, operating income, and loss per share. It also provides a comprehensive management discussion on business strategy, clinical trial progress, and project updates. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and analysis, it is classified as an Interim/Quarterly Report. H1 2019
2019-08-21 English
NeuroVive’s NeuroSTAT project receives FDA Fast Track designation
Regulatory Filings Classification · 1% confidence The document is a press release dated July 27, 2019, announcing that NeuroVive's drug candidate NeuroSTAT received FDA Fast Track designation. This type of announcement, detailing a specific regulatory event (FDA designation) and its implications for drug development, is a standard corporate communication. It is not a full Annual Report (10-K), an Interim Report (IR), a Call Transcript (CT), or a formal Audit Report (AR). Since it is a specific, material announcement that doesn't fit the other specialized categories (like DIRS, DIV, MANG), it falls best under the general category for regulatory or material corporate news that isn't a financial filing. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a press release detailing a regulatory milestone, although it could also be considered a type of 'Capital/Financing Update' (CAP) if the designation directly impacts valuation or partnership discussions, but the core content is regulatory news. Since it is a direct announcement of a regulatory event (FDA designation), RNS is the best fit as a general regulatory announcement/press release.
2019-07-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.